In torturous IPO market, life sciences deals outnumber tech 4 to 1
It is no secret that 2016 has been a torturous period for IPOs, but just how bad is hard to reconcile. Life-sciences deals fell to their slowest six-month pace since 2011 and the environment for technology deals was equally abysmal.
24 August 2016•1 min read
